<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129300">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720576</url>
  </required_header>
  <id_info>
    <org_study_id>R1033-HV-1204</org_study_id>
    <nct_id>NCT01720576</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the safety and tolerability of subcutaneously administered
      REGN1033 (SAR391786) in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of TEAEs</measure>
    <time_frame>Day 1 to Day 141</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint in the study is the incidence and severity of TEAEs (Treatment Emergent Adverse Events) in participants treated with REGN1033 (SAR391786) or placebo, reported from the time of administration of study drug on day 1 (baseline) to day 141 (end of study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN1033 (SAR391786)</measure>
    <time_frame>Day 1 to Day 141</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum concentration of REGN1033 (SAR391786) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>Day 1 to Day 141</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence or absence of anti-REGN1033 (SAR391786) antibodies over time (immunogenicity )</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of REGN1033 (SAR391786) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of REGN1033 (SAR391786) or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of REGN1033 (SAR391786) or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1033 (SAR391786)</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible subjects are males and females aged 60 years and older with no significant health
        issues or clinically significant abnormal laboratory values.

        A subject must meet the following criteria to be eligible for inclusion in the study:

          1. Sexually active males willing to use contraceptives during the study and through 4
             months after the study.

          2. Female subjects not of child bearing potential (surgically sterile or postmenopausal
             for longer than 1 year)

          3. Body mass index (BMI) between 18.5 and 32 kg/m2 inclusive

          4. Willing to maintain current diet and exercise routine for the duration of the study

          5. Willing and able to return for all clinic visits and complete all study-related
             procedures

          6. Able to read and understand, and willing to sign the ICF

        Exclusion Criteria:

          1. Significant concomitant illness such as, but not limited to cardiac, renal,
             rheumatologic, gastrointestinal, hematological, skeletal/muscular, neurologic,
             psychiatric, endocrine, metabolic or immunological disease.

          2. Evidence of malnutrition

          3. Cachexia of any cause

          4. Evidence or history of muscle diseases or weakness with the exception of age related
             muscle loss

          5. Limb amputation

          6. Immobilization, surgical procedure, fracture, or trauma to the upper or lower limb
             within 6 months

          7. History or evidence of heart diseases including but not limited to coronary heart
             disease with/without history of myocardial infarction, chronic or acute heart failure
             (New York Heart Association [NYHA] stage 2-4), cardiac arrhythmia with clinical
             symptoms, valvular heart disease, and cardiac hypertrophy of clinical significance

          8. Women of childbearing potential (not surgically sterile or amenorrheic for at least
             12 months if postmenopausal)

          9. Uncontrolled diabetes defined as HbA1C &gt; 7.5 at screening; if taking oral
             hypoglycemic drugs, have to be on stable doses of medication for more than 3 months.
             Diabetics using insulin are excluded

         10. Asthmatic subjects with current or recurring symptoms within 1 year.

         11. History of, COPD, chronic kidney disease, cancer except primary basal-cell skin
             cancer that has been adequately treated

         12. Neurological injury (eg, stroke) within 1 year

         13. Abnormal or uncontrolled blood pressure at screening visit defined as diastolic BP
             &gt;95 and/or systolic BP &gt;160 mm Hg; if taking hypertensive medication, have to be on
             stable doses of medication for more than 3 months

         14. Hepatic transaminases (ALT and or AST) &gt; 2X ULN

         15. Reduced renal function as defined by eGFR&lt;60 mL/min

         16. Current smokers or previous smokers who stopped smoking within 6 months

         17. Current or recent history (within 1 year of screen) of alcohol or drug abuse

         18. History of hypersensitivity response to any biologics

         19. History of hypersensitivity to doxycycline or other tetracycline antibiotics

         20. Current or recent participation in any clinical trial (within 30 days of small
             molecular drugs or within 3 months of biologics)

         21. Exposure within 3 months to approved biological drugs. (The name of the drug and
             duration of previous exposure will be recorded). Vaccines are allowed.

         22. Sexually active men* who are unwilling to practice adequate contraception during the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
